Company Spotlight: Bunkerhill Contrast CAC - Opportunistic Screening on Routine Scans

We unpack the FDA 510(k) summary for Bunkerhill Contrast CAC, an AI tool cleared to opportunistically detect and quantify coronary artery calcium on routine contrast-enhanced chest CTs. We discuss the shift from non-contrast to contrast imaging, the pivotal performance data, and what it means for clinical workflows.

Key points

Cleared for adults aged 30 years and above to detect and estimate the quantity of coronary artery calcification.Specifically designed to analyze non-gated, contrast-enhanced chest CT images, unlike its predicate device which uses non-contrast scans.Outputs an estimated volume score in mm3 rather than traditional Agatston units.Pivotal testing demonstrated a sensitivity of 0.957 and specificity of 0.929.A 50-case bridging study comparing contrast to non-contrast images showed a mean bias of -4.36 mm3.The software is intended as adjunctive information only and does not replace the physician's evaluation or the original patient report.

Source: FDA 510(k) summary K260166: Bunkerhill Contrast CAC (BunkerHill Health) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-bunkerhill-contrast-cac-opportunistic-screening-on-r-dfb2f3